All Stories

  1. Community-Acquired Pneumonia in Nursing-Home Residents in the Post-HCAP Era
  2. Human Metapneumovirus: An Underestimated Cause of Severe Respiratory Infection
  3. ERS statement: Core outcome set for trials evaluating the management of community-acquired and nosocomial pneumonia in adults
  4. Can better oral care reduce non-ventilator hospital-acquired pneumonia?
  5. Advocacy in Pneumonia
  6. External Validation of the Long-term Pneumonia Mortality Index in a Low- and Middle-Income Country
  7. Eosinopenia and prognosis in severe community-acquired pneumonia
  8. From Acute Infection to Chronic Risk: Reframing Pneumonia Outcomes through Long-Term Mortality Prediction
  9. Phenotype-based stratification and corticosteroid response in hyperinflammatory severe community-acquired pneumonia
  10. Corticosteroids in severe community-acquired pneumonia: friend, foe or both?
  11. Transforming post-acute pneumonia management: risk stratification using machine learning
  12. Nuevas perspectivas en la neumonía adquirida en la comunidad en el adulto
  13. Corticosteroids and hospital-acquired pneumonia
  14. The pneumonia challenge: time to end the global neglect
  15. Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes
  16. Critical Challenges: Respiratory Infections in Immunocompromised ICU Patients
  17. Pulse oximetry to optimise first-line care and save children’s lives: evidence from the AIRE project in West Africa
  18. Why RSV Infection Matter in Older Adults? The Urgent Need for Vaccination
  19. Pulmonary Infections in Patients with Human Immunodeficiency Virus Infection
  20. Identifying predictors of treatment failure with community-acquired pneumonia: an update
  21. Risk Factors and Outcomes Associated With Polymicrobial Infection in Community-Acquired Pneumonia
  22. Inteligencia Artificial en la identificación de la Neumonía Pediátrica en Radiografías de Tórax
  23. Infecciones por el virus respiratorio sincitial en los adultos
  24. Viral community-acquired pneumonia: what’s new since COVID-19 emerged?
  25. Coronavirus Disease 2019 and Emerging Lung Infections in the Immunocompromised Patient
  26. Adult vaccinations against respiratory infections
  27. Healthcare worker views on antimicrobial resistance in chronic respiratory disease
  28. Mechanical power is not associated with mortality in COVID-19 mechanically ventilated patients
  29. World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance
  30. Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia
  31. Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia
  32. Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia
  33. Impact of empirical treatment recommendations of European guidelines for nosocomial pneumonia. A prospective cohort study
  34. Epidemiology, ventilation management and outcomes of COVID–19 ARDS patients versus patients with ARDS due to pneumonia in the Pre–COVID era
  35. A review of the value of point-of-care testing for community-acquired pneumonia
  36. Obtaining patient phenotypes in SARS-CoV-2 pneumonia, and their association with clinical severity and mortality
  37. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia
  38. Diabetes Mellitus and Pneumococcal Pneumonia
  39. The association of premorbid conditions with 6-month mortality in acutely admitted ICU patients over 80 years
  40. Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort
  41. Viral Pneumonia: From Influenza to COVID-19
  42. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
  43. World Pneumonia Day 2023: the rising global threat of pneumonia and what we must do about it
  44. Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis
  45. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review
  46. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantStaphylococcus aureuspneumonia
  47. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?
  48. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia
  49. Interventions to improve outcomes in community-acquired pneumonia
  50. Bacteremia prediction in pneumococcal pneumonia: a comparative study of 2 scores
  51. Levels of inflammatory and cardiac biomarkers as a predictor factor for complications and outcomes in hospitalized COVID-19 patients
  52. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
  53. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
  54. World Pneumonia Day 2023: Reducing the impact of pneumonia in the Americas
  55. A Novel Approach to Temperature Profiling in Relation to Clinical Outcomes in Oncological Patients with Neutropenia
  56. Correction: Promoting the use of social networks in pneumonia
  57. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients
  58. Características clínicas y epidemiológicas de las muertes por dengue durante un brote en el norte del Perú
  59. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report
  60. Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
  61. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
  62. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain
  63. Advances in molecular diagnostic tests for community-acquired pneumonia
  64. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia
  65. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia
  66. Hyperglycemia in Acute Critically Ill COVID-19 Patients
  67. Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia
  68. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia
  69. Host-targeted approaches to sepsis due to community-acquired pneumonia
  70. Differences between sexes concerning COVID-19-related pneumonia
  71. Respiratory viruses: their importance and lessons learned from COVID-19
  72. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia
  73. Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study
  74. COVID-19 in Ventilated Elderly Patients: Data from 52 Intensive Care Units in Spain
  75. Major candidate variables to guide personalized treatment with corticosteroids in critically ill patients with COVID-19: CIBERESUCICOVID study
  76. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
  77. Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome
  78. Aspiration pneumonia
  79. Ceftaroline in severe community-acquired pneumonia
  80. Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
  81. Biomarcadores biológicos en las enfermedades respiratorias
  82. [Translated article] Biological Biomarkers in Respiratory Diseases
  83. What's Next in Pneumonia?
  84. Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis
  85. Severe Infections Due to Respiratory Viruses
  86. One-year mortality after ICU admission due to COVID-19 infection
  87. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study
  88. Management of pneumonia in critically ill patients
  89. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study
  90. COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital
  91. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
  92. Management and outcomes in critically ill nonagenarian versus octogenarian patients
  93. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
  94. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia
  95. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis
  96. Early profiling of low-risk SARS-CoV-2 pneumonia for ward allocation
  97. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  98. Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study
  99. Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial
  100. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study
  101. Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study
  102. Pulse oximetry is an essential tool that saves lives: a call for standardisation
  103. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
  104. Provision of critical care for the elderly in Europe: a retrospective comparison of national healthcare frameworks in intensive care units
  105. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort
  106. Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia
  107. The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011–2018
  108. Pneumonia
  109. Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis
  110. Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain
  111. Frailty is associated with long-term outcome in patients with sepsis who are over 80 years old: results from an observational study in 241 European ICUs
  112. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia
  113. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
  114. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
  115. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study
  116. Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes
  117. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  118. Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience
  119. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community
  120. Awareness and Pneumonia knowledge: where to start educating?
  121. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes
  122. Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease
  123. SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities
  124. The importance of airway and lung microbiome in the critically ill
  125. Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019
  126. Q Fever (Coxiella Burnetii)
  127. Promoting the use of social networks in pneumonia
  128. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens
  129. Advances in molecular diagnostic tests for pneumonia
  130. Validation of the PES Prediction Score for the Causative Different to Treat Microorganisms in Community-Acquired Pneumonia
  131. Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, but…
  132. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
  133. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain
  134. Gender differences in community-acquired pneumonia
  135. Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020
  136. Community-acquired pneumonia in critically ill very old patients: a growing problem
  137. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
  138. Can Artificial Intelligence Improve the Management of Pneumonia
  139. Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation
  140. A multicentre analysis of Nocardia pneumonia in Spain: 2010–2016
  141. Non-invasive ventilation in palliative care: a systematic review
  142. Reply to Musher
  143. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning
  144. An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria
  145. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study
  146. New antibiotics for community acquired pneumonia
  147. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
  148. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia
  149. Risk factors for MDR pneumonia according to the 2017 International ERS/ESICM/ESCMID/ALAT guidelines
  150. Prevalence and risk factors of sepsis in very old patients with CAP
  151. Effect of corticosteroids on inflammatory markers in patients with severe cap and high inflammatory response according to presence of lymphopenia
  152. Follow-up cultures in ventilator-associated pneumonia
  153. Viral Sepsis in Adults with Community-Acquired Pneumonia
  154. Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia
  155. Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?
  156. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia
  157. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis
  158. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  159. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection
  160. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia
  161. non invasive diagnosis of nosocomial pneumonia
  162. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  163. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia
  164. lymphopenia predicts mortality in patients with ICU pneumonia
  165. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
  166. Pure Viral Sepsis Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors
  167. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults
  168. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
  169. PES Pathogens in Severe Community-Acquired Pneumonia
  170. An international perspective on hospitalized patients with viral community-acquired pneumonia
  171. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia
  172. Community-acquired pneumonia as an emergency condition
  173. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia
  174. Reply to Head and Keynan
  175. Drugs that increase the risk of community-acquired pneumonia: a narrative review
  176. LYMPHOPENIA AS PREDICTOR OF LONG TERM MORTALITY IN PATIENTS WITH HOSPITAL ACQUIRED PNEUMONIA
  177. Twenty-year Trend in Mortality among Hospitalized Patients with Pneumococcal Community-Acquired Pneumonia
  178. Acute Respiratory Distress Syndrome in Mechanically-Ventilated Patients with Community-Acquired Pneumonia
  179. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART
  180. Clinical Approach to Community-acquired Pneumonia
  181. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
  182. Inflammatory response depends on time since onset of symptoms in pneumonia
  183. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
  184. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
  185. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  186. Community-acquired bacterial pneumonia in adult HIV-infected patients
  187. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease
  188. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome
  189. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
  190. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study
  191. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
  192. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
  193. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia
  194. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
  195. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  196. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study
  197. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress
  198. Has Mortality of Community-Acquired Pneumonia Really Reduced?
  199. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia
  200. Adjuvant therapies in critical care: steroids in community-acquired pneumonia
  201. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia
  202. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
  203. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
  204. Antimicrobial Treatment of CAP. Is there a higher benefit of macrolides combination in patients with pneumococcal CAP?
  205. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
  206. Interpretation of biomarkers at emergency department depends on onset of symptoms in community-acquired pneumonia
  207. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
  208. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients
  209. Lymphopenic community acquired pneumonia, an unnoticed phenotype associated to mortality in non immuno-suppressed patients: a retrospective cohort study
  210. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
  211. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia
  212. Risk factors for community-acquired pneumonia in adults
  213. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
  214. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia
  215. Research in community-acquired pneumonia: the next steps
  216. Seasonality of pathogens causing community-acquired pneumonia
  217. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns
  218. Laboratory diagnosis of pneumonia in the molecular age
  219. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
  220. Clinical management of community acquired pneumonia in the elderly patient
  221. Community-Acquired Pneumonia 2000-2015: What is New?
  222. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  223. Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
  224. Usefulness of real time-polymerase chain reaction (RT-PCR) in the diagnosis of ICU-acquired pneumonia (ICUAP)
  225. Bacteremic vs. non-bacteremic pneumococcal pneumonia in immunocompetent patients: Predictive and prognostic factors
  226. Response
  227. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
  228. Community-acquired pneumonia related to intracellular pathogens
  229. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
  230. What is the clinical relevance of drug-resistant pneumococcus?
  231. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia
  232. Pneumococcal vaccination
  233. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  234. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
  235. Severe community-acquired pneumonia: Corticosteroids as adjunctive treatment to antibiotics
  236. Bronchiectasis in rare pulmonary diseases: A case series
  237. Bacteraemia in outpatients with community-acquired pneumonia
  238. Polymicrobial community-acquired pneumonia: An emerging entity
  239. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia
  240. The effect of macrolide-resistance on the outcome of patients hospitalized forstreptococcus pneumoniaepneumonia
  241. LATE-BREAKING ABSTRACT: Differences inS. pneumoniaeserotypes distribution causing CAP in hospitalized adults in Spain according to comorbidities by a new urinary antigen detection (UAD) test. The CAPA study
  242. Bacteraemia in outpatient with community-acquired pneumonia
  243. Ceftobiprole for the treatment of pneumonia: a European perspective
  244. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series
  245. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients
  246. New antimicrobial approaches to gram positive respiratory infections
  247. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.
  248. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia
  249. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis
  250. Severe community-acquired pneumonia: Severity and management
  251. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update
  252. Clinical Management of Bacterial Pneumonia
  253. Viral infections
  254. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia
  255. Severity and outcomes of community acquired pneumonia in asthmatic patients
  256. Predicting treatment failure in patients with community acquired pneumonia: a case-control study
  257. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  258. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature
  259. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study
  260. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome
  261. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
  262. Pneumococcal disease: Epidemiology and new vaccines
  263. Community-acquired viral pneumonia in human immunodeficiency virus infected patients
  264. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  265. Predicting Community-Acquired Pneumonia Etiology: Response
  266. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia
  267. IgM levels in plasma predict outcome in severe pandemic influenza
  268. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study
  269. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  270. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  271. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia
  272. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia
  273. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)
  274. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
  275. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
  276. Influenza A (H1N1) Pneumonia
  277. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
  278. Invasive Pneumococcal Disease Today
  279. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
  280. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
  281. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
  282. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes
  283. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes
  284. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia
  285. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia
  286. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza
  287. Community-acquired pneumonia in outpatients: aetiology and outcomes
  288. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients
  289. CAP IN COPD PATIENTS
  290. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
  291. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
  292. Microbial aetiology of community-acquired pneumonia and its relation to severity
  293. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
  294. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients
  295. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic
  296. Correction
  297. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia
  298. Severe Mixed Community Acquired Pneumoniae
  299. Community-acquired Pneumonia In Outpatients: Microbial Etiology
  300. INDICATION OF PLEURAL DRAINAGE IN PARAPNEUMONIC EFFUSION: ADHERENCE TO THE AMERICAN COLLEGE OF CHEST PHYSICIANS’ GUIDELINES
  301. PARAPNEUMONIC EFFUSIONS ACCORDING TO THE CLASSIFICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS: CLINICAL CHARACTERISTICS
  302. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers
  303. Nursing home-acquired pneumonia: a 10 year single-centre experience
  304. Aspiration pneumonia
  305. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).
  306. Community-Acquired Pneumonia: Etiology and Severity Scores.
  307. Complicated Pneumococcal Pneumonia in Adults.
  308. Severe community-acquired pneumonia